drugset / Trial / NCT04445207

Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19

NCT04445207

Expanded access No longer available Jonathan Gerber

Summary

The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic 200 ml Other

Indications